SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.smaller Cos. Regulatory News (BSV)

Share Price Information for Br.smaller Cos. (BSV)

Share Price is delayed by 15 minutes
Get Live Data
73.50    0.50 (0.68%)
Bid:
72.00
Ask:
75.00
Spread: 3.00 (4.167%)
Market Cap: £306.68m
BSV Live PriceLast checked at - London Stock Exchange

Intraday Br.smaller Cos. Share Chart

3rd Quarter Results

19 Mar 2026 07:00

RNS Number : 2203X
British Smaller Companies VCT PLC
19 March 2026
 

British Smaller Companies VCT plc

Interim Management Statement for the quarter ended 31 December 2025

British Smaller Companies VCT plc (the "Company") presents its interim management statement for the quarter ended 31 December 2025. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

In the quarter to 31 December 2025 the Company's Total Return per share increased by 0.65 pence, a 0.8 per cent increase on the opening NAV per share. At 31 December 2025 the NAV per ordinary share totalled 78.70 pence, following payment of a 2.00 pence per share dividend in the quarter. 

Investment Activity

During the quarter, the Company invested £2.7 million into new investment TeamFeePay; and a further £4.1 million into existing portfolio companies Plandek, Xapien, Ohalo and Sipsynergy. Subsequent to the quarter end, the Company invested £3.0 million into existing portfolio company Summize. This takes the total amount invested so far this year to £18.5 million.

In October 2025, the Company realised its investment in Elucidat, receiving £5.5 million in initial proceeds, with additional deferred consideration of £0.7 million anticipated to be received over the next 18 months. To date, the Elucidat investment has generated a 1.3x return on the original cost of £4.3 million. Including deferred consideration, proceeds have the potential to rise to £6.2 million, and the return to 1.45x.

In December 2025, the Company realised its investment in SharpCloud, receiving £8.7 million in initial proceeds, with additional deferred consideration of £0.9 million anticipated to be received over the next two years. To date, the SharpCloud investment has generated a 2.0x return on the original cost of £4.3 million. Including deferred consideration, proceeds have the potential to rise to £9.6 million, and the return to 2.2x.

In December 2025, portfolio company Teraview successfully completed an oversubscribed listing on the Korean Stock Exchange. The Company subsequently realised 34 per cent of its holding prior to 31 December 2025, receiving proceeds of £1.2 million. The balance of the Company's holding was realised post-year end, in January 2026, generating a further £1.8 million of proceeds. Overall, the Teraview investment has generated an 8.1x return on the original cost of £0.4 million.

Post-year end, the Company realised its remaining holding in Vuealta, receiving proceeds of £0.7 million, in line with the valuation at the year end. Overall, the Vuealta investment has generated a 1.5x return on the original cost of £3.6 million.

The Company also realised its investment in Sipsynergy post-year end, with total expected proceeds of c. £0.9 million, in line with the valuation at the year end. This represents a 0.3x return on the original cost of £2.8 million.

 

Performance

The table below sets out movements in key metrics for the Company. 

 

 

30 September 2025

Net increase in Value

Shares issued

Dividends paid

Buyback of shares

Movement

In Period

31 December 2025

Net Assets (£m)

284.0

2.2

1.1

(7.1)

(1.7)

(5.5)

278.5

NAV per share (PPS)

80.05

0.65

-

(2.00)

-

(1.35)

78.70

Cumulative dividends paid (PPS)

186.15

-

-

2.00

-

2.00

188.15

Total Return (PPS)

266.20

0.65

-

-

-

0.65

266.85

Shares in issue

354,664,249

-

1,498,811

-

(2,231,911)

(733,100)

353,931,149

Cumulative dividends paid at 31 December 2025 were 188.15 pence per ordinary share (30 September 2025: 186.15 pence per ordinary share).

The movements in NAV and NAV per ordinary share are set out in the table below:

 

 

£m

Pence per

ordinary share

NAV at 30 September 2025

284.0

80.05

Increase in portfolio value

2.5

0.75

Net operating costs

(0.3)

(0.10)

2.2

0.65

Issue/buy-back of shares

(0.6)

-

Total Return in the period

1.6

0.65

NAV before dividends

285.6

80.70

Dividends paid

(7.1)

(2.00)

NAV at 31 December 2025

 

278.5

 

78.70

 

Dividends and shares in issue

On 19 December 2025 the Company issued 1,498,811 shares under the Company's Dividend Re-investment Scheme (DRIS).

Under its standing buyback authority, on 19 December 2025 the Company purchased 2,231,911 shares at 74.65 pence per share at a cost of £1.7 million. These shares are held in treasury. 

The first allotment of the Company's 2025/26 fundraise took place just after the period end, with £15.6 million of proceeds allotted on 7 January 2026. 19,484,289 shares were allotted, taking the total number of ordinary shares to 373,415,438, with a further 39,260,029 shares held in treasury.

Net assets

Net assets at 31 December 2025 comprised the following:

£000

% of net assets

Unquoted investments at fair value

160,361

57.6

Cash and money market funds

113,825

40.9

Other net assets

4,350

1.5

Net assets

278,536

100.0

Investments

The investment portfolio at 31 December 2025 comprised:

Valuation

£000

Cumulative valuation as a % of net assets

Matillion

19,618

7.0%

Unbiased

16,584

13.0%

Xapien

14,255

18.1%

Vypr

11,315

22.2%

Summize

9,973

25.8%

AutomatePro

9,760

29.3%

DrDoctor

6,276

31.5%

Workbuzz

5,961

33.7%

Plandek

5,902

35.8%

Force24

5,841

37.9%

105,485

37.9%

Other investments

54,876

57.6%

Total investments

160,361

57.6%

 

Portfolio performance

In the quarter to 31 December 2025, the aggregate portfolio valuation increased by £2.5 million. Several portfolio companies are demonstrating strong underlying growth of revenues, which has driven positive revaluation uplifts across several assets. 

Fundraising

The Company announced a new share offer on 25 September 2025, alongside British Smaller Companies VCT2 plc, with the intention of raising up to £85 million, in aggregate, which included an over-allotment facility of £25 million, in aggregate. The offers closed to new Applications on 18 December 2025. Gross Applications of £85 million have been received, of which c.£53 million relate to the Company. The first allotment of £25 million (£15.6 million relating to the Company) took place on 7 January 2026; the second and final allotment will take place between 1 and 2 April 2026.

Outlook

The portfolio continues to develop, with several holdings delivering strong growth during the period. Our active portfolio management approach allows us to stay close to investee companies and support them as they scale. Adding new companies to the portfolio and providing follow-on capital to support their growth remains central to our strategy.

The start of 2026 has seen further macroeconomic volatility, with the conflict in the Middle East adding to a challenging environment. There has also been a more cautious market view of software businesses, which has the potential to weigh on the valuations of portfolio companies in the near term; nonetheless, the portfolio continues to be positioned to benefit from an increasingly AI-led world. This, alongside the Company's strong liquidity position leaves it well-placed to manage downside risks, as well as deploy funds from its recent capital raise into promising new opportunities across the UK. 

We are grateful to shareholders for their continued support.

18 March 2026

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

For further information please contact:

Marcus Karia YFM Equity Partners Tel: 0113 244 1000

Alex Collins Panmure Liberum Tel: 0207 886 2767

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTEAEDPFEDKEAA
Date   Source Headline
1st Jul 20197:28 amRNSTransaction in Own Shares
26th Jun 20191:43 pmRNSAnnual Financial Report Announcement
12th Jun 20191:34 pmRNSDirector/PDMR Shareholding
12th Jun 201910:25 amRNSPayment of dividend and issue of shares
25th Apr 20191:17 pmRNSDividend Declaration
4th Apr 201912:11 pmRNSDirector/PDMR Shareholding
4th Apr 201912:06 pmRNSDirector/PDMR Shareholding
1st Apr 20193:51 pmRNSIssue of Equity
1st Apr 20193:45 pmRNSIssue of Equity and Close of Offers
27th Mar 20198:14 amRNSTransaction in Own Shares and Net Asset Value
26th Mar 20194:29 pmRNSPublication of Supplementary Prospectus
26th Mar 20194:27 pmRNSPublication of Supplementary Prospectus
22nd Mar 20199:03 amRNSInterim Management Statement
15th Feb 20199:58 amRNSPayment of dividend and Allotment of shares
11th Feb 201911:15 amRNSClose of Offers to New Applications
11th Feb 201911:15 amRNSClose of Offers to New Applications
28th Jan 20193:00 pmRNSUtilisation of over-allotment facility
28th Jan 20193:00 pmRNSUtilisation of over-allotment facility
7th Jan 20192:15 pmRNSDividend Declaration
7th Jan 20191:15 pmRNSStatement re Prospectus
7th Jan 20191:15 pmRNSStatement re Prospectus
7th Jan 201911:32 amRNSResult of Meeting
21st Dec 20189:10 amRNSDisposal
20th Dec 201810:18 amRNSTransaction in Own Shares
27th Nov 20186:07 pmRNSPublication of Prospectus
27th Nov 20186:07 pmRNSCircular re Incentive Scheme
27th Nov 20185:49 pmRNSPublication of Prospectus
21st Nov 20181:00 pmRNSHalf-year Report to 30 September 2018
23rd Oct 20181:00 pmRNSStatement re proposed joint fundraising
23rd Oct 20181:00 pmRNSStatement re proposed joint fundraising
27th Sep 20181:24 pmRNSTransaction in Own Shares
20th Sep 20183:03 pmRNSDirector/PDMR Shareholding
5th Sep 20182:56 pmRNSAGM Statement
17th Aug 20188:25 amRNSInterim Management Statement
4th Jul 20184:56 pmRNSTransaction in Own Shares
26th Jun 20181:26 pmRNSAnnual Financial Report
18th May 201810:15 amRNSPayment of interim dividend and issue of shares
12th Apr 20188:06 amRNSDividend Declaration
28th Mar 20188:33 amRNSTransaction in Own Shares
2nd Mar 20187:12 amRNSTransaction in Own Shares
26th Feb 20181:51 pmRNSTransaction in Own Shares
23rd Feb 20189:06 amRNSInterim Management Statement
20th Dec 20178:50 amRNSPurchase of own securities and total voting rights
1st Dec 20179:14 amRNSHalf-year Report
28th Sep 20172:59 pmRNSTransaction in Own Shares
23rd Aug 20176:15 pmRNSInterim Management Statement
3rd Aug 20172:04 pmRNSAppointment of non-executive director
2nd Aug 20178:04 amRNSResult of Annual General Meeting
16th Jun 20171:20 pmRNSAnnual Financial Report Announcement
26th May 201711:26 amRNSPayment of Interim Dividend and Issue of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.